Felbamate-induced headache

Alan B. Ettinger; Lina Jandorf; Ajay Berdia; Mary R. Andriola; Lauren B. Krupp; Deborah M. Weisbrot

doi:10.1111/j.1528-1157.1996.tb00599.x

Felbamate-induced headache

Alan B. Ettinger
, Lina Jandorf
, Ajay Berdia
, Mary R. Andriola
, Lauren B. Krupp
, Deborah M. Weisbrot

Psychiatry

Stony Brook University

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM). Twenty patients (33%) experienced HA. HA was pounding in 11 (55%), steady in 9 (45%), moderate or severe in 19 (95%), occurred at least once a week in all patients, and was relieved by nonnarcotic analgesics in 14 (70%). Mean duration on FBM before HA onset was 19 days. HA occurred with higher FBM doses and was relieved in 8 of 13 patients (62%) with FBM dose reduction. FBM was discontinued in most cases because of risks of anemia or hepatitis; not because of HA. Other side effects included insomnia (25%), gastrointestinal symptoms (27%), and agitation or restlessness (23%). HA is a common dose-related complication of FBM, occurs early after initiation of FBM treatment, and is relieved by dose reduction.

Original language	English
Pages (from-to)	503-505
Number of pages	3
Journal	Epilepsia
Volume	37
Issue number	5
DOIs	https://doi.org/10.1111/j.1528-1157.1996.tb00599.x
State	Published - May 1996

Keywords

Anticonvulsants
Drug toxicity
Felbamate
Headache

Access to Document

10.1111/j.1528-1157.1996.tb00599.x

Cite this

@article{bb9ef923614c4c07bef72d352cc9d5c4,

title = "Felbamate-induced headache",

abstract = "We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM). Twenty patients (33\%) experienced HA. HA was pounding in 11 (55\%), steady in 9 (45\%), moderate or severe in 19 (95\%), occurred at least once a week in all patients, and was relieved by nonnarcotic analgesics in 14 (70\%). Mean duration on FBM before HA onset was 19 days. HA occurred with higher FBM doses and was relieved in 8 of 13 patients (62\%) with FBM dose reduction. FBM was discontinued in most cases because of risks of anemia or hepatitis; not because of HA. Other side effects included insomnia (25\%), gastrointestinal symptoms (27\%), and agitation or restlessness (23\%). HA is a common dose-related complication of FBM, occurs early after initiation of FBM treatment, and is relieved by dose reduction.",

keywords = "Anticonvulsants, Drug toxicity, Felbamate, Headache",

author = "Ettinger, \{Alan B.\} and Lina Jandorf and Ajay Berdia and Andriola, \{Mary R.\} and Krupp, \{Lauren B.\} and Weisbrot, \{Deborah M.\}",

year = "1996",

month = may,

doi = "10.1111/j.1528-1157.1996.tb00599.x",

language = "English",

volume = "37",

pages = "503--505",

journal = "Epilepsia",

issn = "0013-9580",

number = "5",

}

TY - JOUR

T1 - Felbamate-induced headache

AU - Ettinger, Alan B.

AU - Jandorf, Lina

AU - Berdia, Ajay

AU - Andriola, Mary R.

AU - Krupp, Lauren B.

AU - Weisbrot, Deborah M.

PY - 1996/5

Y1 - 1996/5

N2 - We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM). Twenty patients (33%) experienced HA. HA was pounding in 11 (55%), steady in 9 (45%), moderate or severe in 19 (95%), occurred at least once a week in all patients, and was relieved by nonnarcotic analgesics in 14 (70%). Mean duration on FBM before HA onset was 19 days. HA occurred with higher FBM doses and was relieved in 8 of 13 patients (62%) with FBM dose reduction. FBM was discontinued in most cases because of risks of anemia or hepatitis; not because of HA. Other side effects included insomnia (25%), gastrointestinal symptoms (27%), and agitation or restlessness (23%). HA is a common dose-related complication of FBM, occurs early after initiation of FBM treatment, and is relieved by dose reduction.

AB - We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM). Twenty patients (33%) experienced HA. HA was pounding in 11 (55%), steady in 9 (45%), moderate or severe in 19 (95%), occurred at least once a week in all patients, and was relieved by nonnarcotic analgesics in 14 (70%). Mean duration on FBM before HA onset was 19 days. HA occurred with higher FBM doses and was relieved in 8 of 13 patients (62%) with FBM dose reduction. FBM was discontinued in most cases because of risks of anemia or hepatitis; not because of HA. Other side effects included insomnia (25%), gastrointestinal symptoms (27%), and agitation or restlessness (23%). HA is a common dose-related complication of FBM, occurs early after initiation of FBM treatment, and is relieved by dose reduction.

KW - Anticonvulsants

KW - Drug toxicity

KW - Felbamate

KW - Headache

UR - https://www.scopus.com/pages/publications/0029935719

U2 - 10.1111/j.1528-1157.1996.tb00599.x

DO - 10.1111/j.1528-1157.1996.tb00599.x

M3 - Article

C2 - 8617182

AN - SCOPUS:0029935719

SN - 0013-9580

VL - 37

SP - 503

EP - 505

JO - Epilepsia

JF - Epilepsia

IS - 5

ER -

Felbamate-induced headache

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this